Abliva AB (publ)
Abliva AB (publ)
Your view on NEVPF
Overview
What the company does, where it operates, and who runs it.
About Abliva AB (publ)
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ellen K. Donnelly
- Headquarters
- Medicon Village, Lund, SE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ellen K. Donnelly
- Headquarters
- Medicon Village, Lund, SE
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases.
The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury.
It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020.
Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Abliva AB (publ), and the rating behind it. NEVPF last traded at $0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Abliva AB (publ). Starting points for Abliva AB (publ): EPS -$0.09, beta 0.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Abliva AB (publ). Abliva AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Abliva AB (publ). Trailing twelve-month EPS for Abliva AB (publ) stands at -$0.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Abliva AB (publ). Abliva AB (publ) has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Abliva AB (publ) valued side by side against its closest peers. Abliva AB (publ) is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Abliva AB (publ), and how their positions are changing. At a $45.1M market value, institutional positions materially move Abliva AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Abliva AB (publ) executives and directors. Shares of Abliva AB (publ) have traded between $0.01 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Abliva AB (publ). Abliva AB (publ) is a $45.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Abliva AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Abliva AB (publ). Coverage tracks Abliva AB (publ) within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.